Nivolumab produces long-lasting responses in patients with stage IV melanoma

New MEK inhibitor selumetinib is the first effective drug for advanced melanoma of the eye

Anti-PD-1 drug nivolumab shows high and durable clinical activity in patients with advanced melanoma

Adding GM-CSF to ipilimumab improves survival compared to ipilimumab alone

Prevention of squamous cell carcinoma

Immunotherapy in melanoma and other cancers

Intermittent treatment with vemurafenib may prevent lethal drug resistance in melanoma

History of epidermal stem cell use in the clinical setting

Analysing the efficacy of treatment through Response Evaluation Criteria in Solid Tumors (RECIST)

Phase III MISSION trial: Sorafenib does not extend overall survival as third or fourth line therapy in lung cancer

Trametinib and dabrafenib combination therapy against metastatic melanoma

BRAF inhibitor dabrafenib alone vs combination with MEK1/2 inhibitor trametinib for melanoma